

## China Cord Blood Corporation Files Its Annual Report on Form 20-F

**HONG KONG, China, July 25, 2017 - China Cord Blood Corporation** (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2017. The Form 20-F can be accessed by visiting the U.S. Securities and Exchange Commission’s website at <http://www.sec.gov> and also be found at the Investor Relations section of CCBC’s website at <http://ir.chinacordbloodcorp.com>. CCBC will provide a hard copy of the Annual Report, including a complete set of audited financial statements, free of charge to its shareholders upon request.

### About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at <http://www.chinacordbloodcorp.com>.

### Safe Harbor Statement

*This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.*

### For more information, please contact:

China Cord Blood Corporation  
Investor Relations Department  
Tel: (+852) 3605-8180  
Email: [ir@chinacordbloodcorp.com](mailto:ir@chinacordbloodcorp.com)

ICR, Inc.  
William Zima  
Tel: (+86) 10-6583-7511 (China) or (+1) 646-405-5185 (U.S.)  
Email: [william.zima@icrinc.com](mailto:william.zima@icrinc.com)